首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   58篇
  免费   7篇
  2020年   2篇
  2018年   3篇
  2017年   2篇
  2016年   2篇
  2015年   2篇
  2013年   9篇
  2012年   3篇
  2011年   3篇
  2010年   2篇
  2009年   1篇
  2008年   3篇
  2007年   2篇
  2004年   1篇
  2003年   4篇
  2002年   5篇
  2001年   1篇
  2000年   3篇
  1999年   2篇
  1998年   2篇
  1991年   1篇
  1990年   2篇
  1988年   1篇
  1987年   3篇
  1985年   1篇
  1984年   2篇
  1975年   1篇
  1972年   1篇
  1971年   1篇
排序方式: 共有65条查询结果,搜索用时 15 毫秒
61.
Cognitive enhancing substances such as amphetamine and modafinil have become popular in recent years to improve acute cognitive performance particularly in environments in which enhanced cognition or intelligence is required. Nutraceutical nootropics, which are natural substances that have the ability to bring about acute or chronic changes in cognition have also been gaining popularity in a range of settings and applications including the workplace, driving and in the amelioration of age related cognitive decline. Huperzine A, Vinpocetine, Acetyl-l-carnitine, Rhodiola Rosea and Alpha-lipoic Acid are popular nutritional supplements that have shown promising benefits in improving a range of biological (e.g., blood flow, anti-inflammatory, anti-oxidant, and direct neurotransmitter effects) and cognitive processes from in vitro, animal and human clinical research. We report here the first human randomized clinical trial for cognition in which we administer a combination of Huperzine A, Vinpocetine, Acetyl-l-carnitine, R. Rosea and Alpha-lipoic acid (called Ceretrophin) vs placebo. Sixty participants (40 females and 20 males, with a mean age of 45.4 years, SD = 12.6) completed either the odd or even items from the Raven Advanced Progressive Matrices (APM) at baseline and the opposite odd or even items at week 4 after consuming either the combination nootropic or placebo. A significant study visit (time) × treatment condition interaction was found: F (1, 57) = 7.279, p = 0.009, partial η2 = .113, with paired samples t-tests revealing a significant improvement in mean APM score from baseline to retest (week 4) (t(34) = ? 4.045, p < .001) for the Ceretrophin? group. Improvements in APM scores could be attributed to the active intervention over the placebo, indicating that the treatment improved general intelligence. Implications for improving our understanding of the biological basis of intelligence and pharmacologically improving human cognition are discussed.  相似文献   
62.
63.
64.
65.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号